A citation-based method for searching scientific literature

Alexia Piperidou, Charalampos Loutradis, Pantelis Sarafidis. J Hum Hypertens 2021
Times Cited: 4







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
95
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Annabelle M Warren, Søren T Knudsen, Mark E Cooper. Expert Opin Ther Targets 2019
65
25

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
25

The incidence and implications of aldosterone breakthrough.
Andrew S Bomback, Philip J Klemmer. Nat Clin Pract Nephrol 2007
258
25

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Jackson T Wright, George Bakris, Tom Greene, Larry Y Agodoa, Lawrence J Appel, Jeanne Charleston, DeAnna Cheek, Janice G Douglas-Baltimore, Jennifer Gassman, Richard Glassock,[...]. JAMA 2002
25

Effects of Intensive BP Control in CKD.
Alfred K Cheung, Mahboob Rahman, David M Reboussin, Timothy E Craven, Tom Greene, Paul L Kimmel, William C Cushman, Amret T Hawfield, Karen C Johnson, Cora E Lewis,[...]. J Am Soc Nephrol 2017
193
25

Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.
Pantelis A Sarafidis, Anastasios N Lasaridis. Nat Rev Nephrol 2010
10
25

Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.
ChongTing Lin, Qing Zhang, HuiFang Zhang, AiXia Lin. J Clin Hypertens (Greenwich) 2016
54
25

Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
Pantelis A Sarafidis, Evangelos Memmos, Maria-Eleni Alexandrou, Aikaterini Papagianni. Curr Pharm Des 2018
6
25

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Andrew A House, Christoph Wanner, Mark J Sarnak, Ileana L Piña, Christopher W McIntyre, Paul Komenda, Bertram L Kasiske, Anita Deswal, Christopher R deFilippi, John G F Cleland,[...]. Kidney Int 2019
80
25

US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States.
Rajiv Saran, Bruce Robinson, Kevin C Abbott, Jennifer Bragg-Gresham, Xiaoying Chen, Debbie Gipson, Haoyu Gu, Richard A Hirth, David Hutton, Yan Jin,[...]. Am J Kidney Dis 2020
233
25

Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations From VERTIS CV.
David Z I Cherney, Darren K McGuire, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong,[...]. Circulation 2021
7
25

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
132
25

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
David C Wheeler, Bergur V Stefansson, Mikhail Batiushin, Oleksandr Bilchenko, David Z I Cherney, Glenn M Chertow, Walter Douthat, Jamie P Dwyer, Elizabeth Escudero, Roberto Pecoits-Filho,[...]. Nephrol Dial Transplant 2020
38
25

Prevalence of chronic kidney disease in the United States.
Josef Coresh, Elizabeth Selvin, Lesley A Stevens, Jane Manzi, John W Kusek, Paul Eggers, Frederick Van Lente, Andrew S Levey. JAMA 2007
25


Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
638
25


Eplerenone in patients with systolic heart failure and mild symptoms.
Faiez Zannad, John J V McMurray, Henry Krum, Dirk J van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J Pocock, Bertram Pitt. N Engl J Med 2011
25


A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases.
Kitty J Jager, Csaba Kovesdy, Robyn Langham, Mark Rosenberg, Vivekanand Jha, Carmine Zoccali. Kidney Int 2019
46
25

Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.
Panagiotis I Georgianos, Pantelis A Sarafidis, Vassilios Liakopoulos, Elias V Balaskas, Pantelis E Zebekakis. J Clin Hypertens (Greenwich) 2016
4
25

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial.
João Pedro Ferreira, Paula Abreu, John J V McMurray, Dirk J van Veldhuisen, Karl Swedberg, Stuart J Pocock, John Vincent, Katharina Lins, Patrick Rossignol, Bertram Pitt,[...]. Eur J Heart Fail 2019
20
25


Chronic kidney disease.
Andrew S Levey, Josef Coresh. Lancet 2012
957
25

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
96
25

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
25

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
291
25

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack,[...]. Nephrol Dial Transplant 2020
12
25

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
George Bakris, Megumi Oshima, Kenneth W Mahaffey, Rajiv Agarwal, Christopher P Cannon, George Capuano, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene,[...]. Clin J Am Soc Nephrol 2020
16
25

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Am J Nephrol 2019
52
25

Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
Matthew R Weir, Jay I Lakkis, Bernard Jaar, Michael V Rocco, Michael J Choi, Holly J Kramer, Elaine Ku. Am J Kidney Dis 2018
32
25


Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.
Yoshihiro Matsumoto, Yasuo Mori, Shinji Kageyama, Kazuo Arihara, Toshikazu Sugiyama, Hiromichi Ohmura, Toru Yakushigawa, Hatsumi Sugiyama, Yasushi Shimada, Youichi Nojima,[...]. J Am Coll Cardiol 2014
136
25

The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Charalampos Loutradis, Eirini Papadopoulou, Marietta Theodorakopoulou, Asterios Karagiannis, Pantelis Sarafidis. Future Med Chem 2019
14
25

Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
F Zannad, M Kessler, P Lehert, J P Grünfeld, C Thuilliez, A Leizorovicz, P Lechat. Kidney Int 2006
226
25

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
L Y Agodoa, L Appel, G L Bakris, G Beck, J Bourgoignie, J P Briggs, J Charleston, D Cheek, W Cleveland, J G Douglas,[...]. JAMA 2001
717
25

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.
William G Herrington, David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J Hauske, Jyothis T George, Jennifer B Green, Martin J Landray, Colin Baigent,[...]. Clin Kidney J 2018
97
25

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
25

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
779
25

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
25

Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT.
Pantelis Sarafidis, Charalampos Loutradis, Alberto Ortiz, Luis M Ruilope. Clin Kidney J 2020
5
25

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur J Heart Fail 2016
25

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
188
25

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
217
25

The systemic nature of CKD.
Carmine Zoccali, Raymond Vanholder, Ziad A Massy, Alberto Ortiz, Pantelis Sarafidis, Friedo W Dekker, Danilo Fliser, Denis Fouque, Gunnar H Heine, Kitty J Jager,[...]. Nat Rev Nephrol 2017
111
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.